Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01560663
Recruitment Status : Recruiting
First Posted : March 22, 2012
Last Update Posted : March 9, 2017
UNC Lineberger Comprehensive Cancer Center
Hospital Universitario Ramon y Cajal
Hospital San Carlos, Madrid
Centro Nacional de Investigaciones Oncologicas CARLOS III
Information provided by (Responsible Party):
Miguel Martín Jiménez, Hospital General Universitario Gregorio Marañon

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2017
  Estimated Study Completion Date : June 2017